Apixaban 0.25-mg/mL Suspension for Enteral Feeding Tube

A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

LEARN MORE

Apixaban 0.25-mg/mL Suspension for Enteral Feeding Tube

Author(s): Allen Loyd V Jr

Issue: Jul/Aug 2021 - Volume 25, Number 4
View All Articles in Issue

Page(s): 320

Apixaban 0.25-mg/mL Suspension for Enteral Feeding Tube Page 1

Download in electronic PDF format for $65

Abstract: A formulation for preparing Apixaban 0.25-mg/mL Suspension for Enteral Feeding Tube. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords: Loyd V. Allen Jr., PhD, RPh, formulation, apixaban, oral suspension, enteral feeding tubes, selective factor Xa inhibitor, postoperative thromboprophylaxis, blood clots, deep vein thrombosis, pulmonary embolism

Related Categories: FORMULATIONS, CARDIOLOGY, DOSAGE FORMS/DRUG CARRIERS, HEMOSTASIS, BLEEDING, ANTICOAGULATION, SURGERY

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
Apixaban 0.25-mg/mL Suspension for Enteral Feeding Tube Allen Loyd V Jr	Jul/Aug 2021 Pg. 320
Basics of Compounding: Vehicle for Drug Administration via Enteral Feeding Tubes Allen Loyd V Jr	May/Jun 2022 Pg. 214-217
Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh Allen Loyd V Jr	Nov/Dec 2003 Pg. 449-450
Compounding Rifampin Suspensions with Improved Injectability for Nasogastric Enteral Feeding Tube Administration de Villiers Melgardt M, Vogel Laura, Bogenschutz Monica C, Fingerhut Bonnie J, D'Silva Joseph B, Moore Anne	May/Jun 2010 Pg. 250-256
Recommendations for Compounding Medications for Feeding Tube Administration Klang Mark	Jul/Aug 2010 Pg. 276-282
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Allen Loyd V Jr	Nov/Dec 2022 Pg. 446-466
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K	Jan/Feb 2013 Pg. 74-85 View Sample
Imatinib 40-mg/mL Oral Suspension Allen Loyd V Jr	Nov/Dec 2016 Pg. 510
Atomoxetine 4-mg/mL Oral Solution/Suspension Allen Loyd V Jr	Jul/Aug 2021 Pg. 321
Stability of Clopidogrel in Three Extemporaneously Compounded Oral Liquid Preparations Yamreudeewong Weeranuj, Dolence Eric Kurt, Teixeira M Glaucia	Sep/Oct 2011 Pg. 435-437

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions